Amgen is advancing a dedicated Phase III study to switch patients from weekly GLP-1 injectables to MariTide on every-8-week or quarterly dosing.
Amgen expects to spend about $2.6 billion in 2026 to scale manufacturing capacity, including preparation for MariTide's launch.
Amgen plans six additional country launches for TEPEZZA in the coming months, extending the thyroid eye disease franchise beyond the U.S. and Japan.
Amgen is advancing IMDELLTRA into earlier lines of small cell lung cancer through Phase III studies that could expand the U.S. addressable population to about 28,000 patients.
Amgen raised its 2026 revenue and non-GAAP EPS guidance after first-half execution, citing continued momentum from its six key growth drivers.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Amgen Inc. and 4,900+ companies.